B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 641-648

  Kanda, Mitsuro ^a   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Oya, Hisaharu ^a   Hibino, Soki ^a   Shimizu, Dai ^a   Takami, Hideki ^a   Hashimoto, Ryoji ^a   Okamura, Yukiyasu ^b   Yamada, Suguru ^a   Fujii, Tsutomu ^a   Nakayama, Goro ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

Author keywords

B cell translocation gene 1; Expression; Hepatocellular carcinoma; Prognosis; Tumor suppressor

Indexed keywords

B CELL TRANSLOCATION GENE 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; BTG1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOMA CELL LINE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; BIOSYNTHESIS; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; KAPLAN MEIER METHOD; LIVER TUMOR; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84918497376     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2762     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
3. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (Suppl 1): S27-S34, 2004.
4. Minguez B and Lachenmayer A: Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers 31: 181-190, 2011.
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Miki D, Ochi H, Hayes CN, Aikata H and Chayama K: Hepatocellular carcinoma: towards personalized medicine. Cancer Sci 103: 846-850, 2012.
7. Herath NI, Leggett BA and MacDonald GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis (Review). J Gastroenterol Hepatol 21: 15-21, 2006.
8. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55-76, 2007.
9. Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (Review). Int J Oncol 42: 1133-1138, 2013.
10. Bird A: Perceptions of epigenetics. Nature 447: 396-398, 2007.
11. Khare S, Zhang Q and Ibdah JA: Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol 19: 5439-5445, 2013.
12. Kanda M, Nomoto S, Okamura Y, et al: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 35: 477-483, 2009.
13. Hernandez-G ea V, Toffanin S, Friedman SL and Llovet JM: Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144: 512-527, 2013.
14. Kanda M, Nomoto S, Nishikawa Y, et al: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 98: 190-196, 2008.
15. Takami H, Kanda M, Oya H, et al: Evaluation of MAGE- D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol 108: 557-562, 2013.
16. Cho JW, Kim JJ, Park SG, et al: Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics 4: 3456-3463, 2004.
17. Lin WJ, Gary JD, Yang MC, Clarke S and Herschman HR: The mammalian immediate-early TI S21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem 271: 15034-15044, 1996.
18. Rouault JP, Rimokh R, Tessa C, et al: BTG 1, a member of a new family of antiproliferative genes. Emb o J 11: 1663-1670, 1992.
19. Prévôt D, Voeltzel T, Birot AM, et al: The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation. J Biol Chem 275: 147-153, 2000.
20. Zhao Y, Gou WF, Chen S, Takano Y, Xiu YL and Zheng HC: BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas. Int J Mol Sci 14: 19670-19680, 2013.
21. Sheng SH, Zhao CM and Sun GG: BTG 1 expression correlates with the pathogenesis and progression of breast carcinomas. Tumour Biol 35: 3317-3326, 2014.
22. Kanda M, Nomoto S, Okamura Y, et al: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 50: 571-579, 2011.
23. Nomoto S, Kanda M, Okamura Y, et al: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFE MP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 17: 923-932, 2010.
24. Okamura Y, Nomoto S, Kanda M, et al: Reduced expression of reelin (RELN ) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol 18: 572-579, 2011.
25. Kanda M, Knight S, Topazian M, et al: Mutant GNA S detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62: 1024-1033, 2013.
26. Kanda M, Matthaei H, Wu J, et al: Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142: 730-733, 2012.
27. Kanda M, Sadakari Y, Borges M, et al: Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 11: 719-730, 2013.
28. Hibino S, Kanda M, Oya H, et al: Reduced expression of DENN D2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep 31: 693-700, 2014.
29. Shimizu D, Kanda M, Nomoto S, et al: Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep 31: 1305-1313, 2014.
30. Kanda M, Nomoto S, Oya H, et al: Downregulation of DENN D2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol 44: 44-52, 2014.
31. Kanda M, Shimizu D, Nomoto S, et al: Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer: Apr 3, 2014 (Epub ahead of print).
32. Kawamura-Tsuzuku J, Suzuki T, Yoshida Y and Yamamoto T: Nuclear localization of Tob is important for regulation of its antiproliferative activity. Oncogene 23: 6630-6638, 2004.
33. Rodier A, Rochard P, Berthet C, et al: Identification of functional domains involved in BTG 1 cell localization. Oncogene 20: 2691-2703, 2001.
34. Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 222: 66-72, 2010.
35. Buitenkamp TD, Pieters R, Zimmermann M, et al: BTG 1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia. Leukemia 27: 251-252, 2013.
36. Lee H, Cha S, Lee MS, Cho GJ, Choi WS and Suk K: Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia. J Immunol 171: 5802-5811, 2003.
37. Waanders E, Scheijen B, van der Meer LT, et al: The origin and nature of tightly clustered BTG 1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet 8: e1002533, 2012.
38. Berthet C, Guéhenneux F, Revol V, et al: Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells 7: 29-39, 2002.
39. van Galen JC, Kuiper RP, van Emst L, et al: BTG 1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood 115: 4810-4819, 2010.
40. Pal S and Sif S: Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol 213: 306-315, 2007.